U.S., Nov. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07235891) titled 'Retinal Protective Effects of Novel Finerenone in Patients With Chronic Kidney Disease' on Sept. 16.
Brief Summary: Interestingly, A hypothesis-generating analysis was conducted from two studies using routine ophthalmological examinations from clinical trial participants (ReFineDR/DeFineDR), suggesting a potential benefit of finerenone in the delay of progression of non-proliferative diabetic retinopathy (NPDR), independent of baseline HbA1c. Potential benefits of finerenone were also observed in the prevention of required ocular interventions. However, the studies relied on routine ophthalmological examinations done retrospectively...